License To CRISPR IP To Be Offered By Merck & Broad Institute
--Sharing is Caring--

License To CRISPR IP To Be Offered By Merck & Broad Institute

The Broad Institute of MIT Harvard and Merck have agreed to a framework through which they will offer non-exclusive licenses to CRISPR IP for use in commercial research and product development – an initiative to promote innovation.

Under this agreement – Company using CRISPR tech in their research and development activities can license both sets of IP through the Broad Institute with each partner controlling their own IP, the Broad institute plans to offer licenses to Merck and Broad Institute’s CRISPR IP portfolios to potential licensees for internal research uses.

MIT and Merck stated that their framework is designed to allow other key patent holders to participate in the future – they can participate either through this framework or via a third-party patent pool or collaboration in order to further streamline non-exclusive access to key CRISPR technology.

Merck, Life science CEO Udit Batra stated that – together with the Broad Institute, they aim to simplify the path to licensing CRISPR technology, which will make it more widely available to the global research and discovery community. Via this agreement, they seek to ease up the research activities of their customers – by shortening the drug development timelines for various disease for which to date no cure exists.

See Also
Stem Cell Grown Mini Kidneys Provides In-depth Insights Into Kidney Diseases

Merck KGaA’s Life Sciences Business – MilliporeSigma’s IP for CRISPR technology offered under the Sigma-Aldrich portfolio brand, will become available royalty-free to non-profit academic institutions, non-profit business communities, and governmental agencies for their internal research, consistent with the Broad Institute’s long-standing practice and requirements.

The Broad MIT and Merck also stated that the licenses will follow their respective ethical licensing considerations, which exclude certain CRISPR technology applications, such as for any clinical human germline editing. The Broad Institute also outlines institutional policies on IP licensing on its website.

Along with Merck & Broad Institute – The licensing framework also includes certain Broad IP co-owned with other institutions such as Harvard and MIT, the New York Genome Center, New York University, the Rockefeller University, the University of Iowa Research Foundation, the University of Tokyo, the Whitehead Institute for Biomedical Research, and others.

Source

Download This Notification